The treatment of asthma and inflammatory lung diseases is increasingly moving towards personalised medicine: 2023 has seen the availability in Belgium of two new biotherapies for patients suffering from severe asthma, and the possible use of mepolizumab in certain chronic inflammatory diseases. Finally, the reimbursement of allergen immunotherapy against house dust mites enables a more extended use of this therapeutic option in mild to moderate asthma. All these factors underline the importance of a careful phenotyping of patients prior to treatment.
Keywords
Asthma, biotherapy, immunotherapy